Fig. 1From: Proceedings of the Canadian society of allergy and clinical immunology annual scientific meeting 2015Comparison of the ORBCoN audit findings for IVIg utilization in Ontario to Octagam® 10 % utilization across three Canadian Institutions highlighting labeled, off-label and potentially indicated, versus off-label and not indicated usageBack to article page